Tagged with BI

Spain Spanish biotech ALGENEX is using insect pupae to develop high-purity vaccines more quickly and at a lower cost than conventional production methods. Having secured further investment from outside of Spain, ALGENEX is now looking to produce its first vaccine for European regulators using insect-based production methods. We realised the huge…

UK Having recently been able to present positive data for their lead technology IMCgp100 in uveal melanoma at the American Society of Clinical Oncology (ASCO), Immunocore looks at its future as a homegrown British biotech with confidence. Its CEO Andrew Hotchkiss also shares some of the up-coming investigation programmes for Immunocore’s…

3D Bioprinting With the US FDA approval of a 3D bioprinted drug in 2016, the floodgates have been opened for a new wave of innovative, personalized and customizable printed medicine.   Printing tailored medicine could simplify our supply chain dramatically. Martin Wallace, GSK   3D Bioprinting on the Rise Many healthcare and…

Canada Canada’s medical cannabis market is valued as a USD 1.3 billion market opportunity, with the recreational market potential worth over USD eight billion. Ontario is the Canadian state with by far the largest number of licensed cannabis producers with 57 compared to just 22 in second-placed British Colombia and seven…

Global The global regulatory landscape for medical cannabis, showing the countries in which medical cannabis and cannabinoid treatments are legal / essentially legal, illegal but often unenforced, decriminalized, and illegal.   Made with Visme Infographic Maker   Click here to download our report on Canada’s world-leading medical cannabis industry

Hong Kong The Hon. Fanny Law Fan Chiu-fun, chairperson, and Prof. Daniel Lee, head of the Biomedical Technology Cluster, at Hong Kong Science and Technology Parks Corporation (HKSTP) provide an update on Hong Kong’s biotech scene, government commitment to innovation, and Hong Kong’s role within the wider Greater Bay Area project. We had…

UK As the UK extracts itself from the European Union, key figures from the country’s life sciences sector are split on the implications of Brexit for their industry. “The UK pharmaceutical industry and the patients who rely on it are under serious threat from Brexit” Erik Nordkamp, Pfizer Erik Nordkamp, the…

Spain Jose Manuel Rigueiro, general manager of the Spanish affiliate of Actelion, discusses the lack of trust between health authorities and the industry and the challenges of launching new orphan drugs in such a fragmented healthcare system. He highlights the successful launch of Uptravi® and his commitment to avoid business disruption…

Cannabis One area in which the island nation of Malta has been a first mover in embracing disruption has been its controversial entry into the global cannabinoid market. The medical cannabis market within the EU is expected to be worth USD 56 billion by 2020 with leading European nations such as…

Malta Dino Mangion, head of Malta Operations at Medichem-Combino Pharm, has been leading the company through the harmonization of operations between Medichem and Combino Pharm and explains his strategy to increase the synergies between the two sites as well as the key advantages of Malta for manufacturers. As Head of Malta…

Spain Carlos Teixeira, CEO of Teva Spain and Portugal, discusses the challenges the generic sector is facing in Spain, which ultimately spurred the company towards other business opportunities, and highlights the significant footprint of the Spanish affiliate, with its manufacturing site in Zaragoza serving as an export base for Europe and…

Cannabis While many Canadian medical cannabis outfits cover the entire value chain, from research and development through to manufacturing and distribution, others – such as Canopy Health and Tetra Bio-Pharma – are taking their cues from the biotechnology industry and strictly focusing on clinical trials.   I believe that across the…